SEC Form 4 · accession 0001140361-18-023474
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Apr 30, 2018
Accepted (ET)
May 14, 2018 · 9:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 30, 2018 | A | 309 | $68.782 | A | 290,600 | D | |
| Common StockF3 | May 10, 2018 | M | 18,750 | $38.59 | A | 309,350 | D | |
| Common StockF3,F4 | May 10, 2018 | S | 18,750 | $89.589 | D | 290,600 | D | |
| Common StockF3 | May 11, 2018 | M | 18,750 | $38.59 | A | 309,350 | D | |
| Common StockF3,F5 | May 11, 2018 | S | 18,750 | $88.419 | D | 290,600 | D | |
| Common Stock | holding | — | — | — | 182,201 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F3,F6 | $38.59 | May 10, 2018 | M | 18,750 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 18,750 | 93,750 | D |
| Stock Option (Right to buy Common Stock)F3,F6 | $38.59 | May 11, 2018 | M | 18,750 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 18,750 | 75,000 | D |
Explanation of responses
- F1Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan.
- F2Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 312 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 52 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018.
- F3Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
- F4The price in column 4 is the weighted average price. The price actually received ranged from $89.055 to $90.170. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F5The price in column 4 is the weighted average price. The price actually received ranged from $87.75 to $89.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F6Reflects the number of options outstanding after the transactions from this specific stock option grant.